Trial reportJAMA network open2022
Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial.
Trial report in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01852123 (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome: A Randomized Controlled Trial
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Utility of biomarkers in patients with a type 2 myocardial infarction: a systematic review.Open heart · 2026Pooled it
- Trial
- Contemporary Challenges and Strategies for Diagnosing and Managing in Type 2 Myocardial Infarction: A Narrative Review.Journal of personalized medicine · 2026Review
- Identification and validation of brown adipocyte-related key genes in ST-segment elevated myocardial infarction.Journal of cardiothoracic surgery · 2026Article
- Maximum Troponin As an Independent Predictor of 30- and 90-day Mortality in Type 2 Myocardial Infarction.Critical pathways in cardiology · 2026Article
- Characteristics and outcomes of type 2 myocardial infarction in sepsis survivors.Frontiers in cardiovascular medicine · 2026Article
- Article
- An easy-to-use model for screening type 2 myocardial infarction in geriatric patients with acute coronary syndrome: a retrospective cohort study.Frontiers in medicine · 2026Article
- The assessment and management of patients with type 2 myocardial infarction: an international Delphi study.European heart journal. Quality of care & clinical outcomes · 2025Article
- Implications of a new clinical classification of acute myocardial infarction.European heart journal. Acute cardiovascular care · 2025Observational
- Type 2 myocardial infarction: challenges in diagnosis and treatment.European heart journal · 2025Review
- A gender-integrated biopsychosocial model to understand cardiovascular risk in women working under environmental hazards: the case of chronic intermittent hypoxia.Frontiers in public health · 2025Review
- Sevoflurane Suppresses Cardiomyocyte Pyroptosis in Myocardial Ischemia via NLRP3 Inflammasome Signaling.Analytical cellular pathology (Amsterdam) · 2025Article
- Application of the Universal Definition of Myocardial Infarction in Clinical Practice in Scotland and Sweden.JAMA network open · 2024Article
- Error in Byline.JAMA network open · 2023Article
- The diagnostic role of cardiac troponin I beyond acute myocardial infarction.Annals of translational medicine · 2023Article
- Improving Risk Stratification for Patients With Type 2 Myocardial Infarction.Journal of the American College of Cardiology · 2023Article
Corrections and comments
- Erratum issuedError in Byline.2023
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Importance: Type 2 myocardial infarction occurs owing to multiple factors associated with myocardial oxygen supply-demand imbalance, which may confer different risks of adverse outcomes. Objective: To evaluate the prevalence and outcomes of different factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction. Design, Setting, and Participants: In this secondary analysis of a stepped-wedge, cluster randomized clinical trial conducted at 10 secondary and tertiary care hospitals in Scotland, 6096 patients with an adjudicated diagnosis of type 1 or type 2 myocardial infarction from June 10, 2013, to March 3, 2016, were identified, and the findings were reported on August 28, 2018. The trial enrolled consecutive patients with suspected acute coronary syndrome. The diagnosis of myocardial infarction was adjudicated according to the Fourth Universal Definition of Myocardial Infarction and the primary factor associated with oxygen supply-demand imbalance in type 2 myocardial infarction was defined. This secondary analysis was not prespecified. Statistical analysis was performed from July 7 to 30, 2020. Intervention: Implementation of a high-sensitivity cardiac troponin I assay. Main Outcomes and Measures: All-cause death at 1 year according to the factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction. Results: Of 6096 patients (2602 women [43%]; median age, 70 years [IQR, 58-80 years]), 4981 patients had type 1 myocardial infarction, and 1115 patients had type 2 myocardial infarction. The most common factor associated with oxygen supply-demand imbalance was tachyarrhythmia (616 of 1115 [55%]), followed by hypoxemia (219 of 1115 [20%]), anemia (95 of 1115 [9%]), hypotension (89 of 1115 [8%]), severe hypertension (61 of 1115 [5%]), and coronary mechanisms (35 of 1115 [3%]). At 1 year, all-cause mortality occurred for 15% of patients (720 of 4981) with type 1 myocardial infarction and 23% of patients (285 of 1115) with type 2 myocardial infarction. Compared with patients with type 1 myocardial infarction, those with type 2 myocardial infarction owing to hypoxemia (adjusted odds ratio [aOR], 2.35; 95% CI, 1.72-3.18) and anemia (aOR, 1.83; 95% CI, 1.14-2.88) were at greatest risk of death, whereas those with type 2 myocardial infarction owing to tachyarrhythmia (aOR, 0.83; 95% CI, 0.65-1.06) or coronary mechanisms (aOR, 1.07; 95% CI, 0.17-3.86) were at similar risk of death as patients with type 1 myocardial infarction. Conclusions and Relevance: In this secondary analysis of a randomized clinical trial, mortality after type 2 myocardial infarction was associated with the underlying etiologic factor associated with oxygen supply-demand imbalance. Most type 2 myocardial infarctions were associated with tachyarrhythmia, with better prognosis, whereas hypoxemia and anemia accounted for one-third of cases, with double the mortality of type 1 myocardial infarction. These differential outcomes should be considered by clinicians when determining which cases need to be managed if patient outcomes are to improve. Trial Registration: ClinicalTrials.gov Identifier: NCT01852123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.